Advertisement
News
Subscribe to MDT Magazine News

Aegerion gains orphan drug status for lipid disorder drug

March 16, 2011 10:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Aegerion Pharmaceuticals Inc., a lipid disorder treatment firm in Cambridge, has been granted orphan drug designation from the U.S. Food and Drug Administration for its treatment of familial chylomicronemia (FC), a rare genetic disorder.

TOPICS:

Predatory Practices in Teleradiology: Fact or Fiction?

March 16, 2011 10:34 am | by Diagnostic Imaging | Comments

In response to a recent JACR article, the managing partner at one teleradiology company argues that not all teleradiology companies are predatory and competitive. Most in the industry benefit radiologists, he argues, by providing cost-effective technologies, streamlined administrative...

TOPICS:

Cambridge startup ImmusanT launches with celiac therapy

March 16, 2011 9:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Born from research in Australia, new Cambridge startup ImmusanT Inc. has launched to commercialize a therapy that aims to treat celiac disease like a simple allergy with regular injections of a therapy.

TOPICS:
Advertisement

New Pro-Pharmaceuticals CEO Traber aims to steer company's recovery

March 16, 2011 9:33 am | by Mass High Tech: The Journal of New England Technology | Comments

When Peter Traber joined Pro-Pharmaceuticals Inc.'s board a couple years ago, the Newton-based company was running on fumes, the result of poorly constructed financial deals. But today, the new CEO and interim chief scientific officer is full of optimism, saying the company has turned around.

Netsmart Technologies Named NACo Premier Partner of the Year

March 16, 2011 9:32 am | by Bio-Medicine.Org | Comments

WASHINGTON, March 16, 2011 /- Netsmart Technologies, Inc., a leading provider of software and services for health and human services organizations, has been presented with the National Association of Counties' (NACo) Premier Partner of the Year Award. Each March during the association's...

TOPICS:

FDA, EMA Announce Pilot for Parallel Assessment of Quality by Design Applications

March 16, 2011 9:32 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 16, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration and the European Medicines Agency (EMA) have launched a new pilot program that will allow parallel evaluation of relevant development and manufacturing data components, known as Quality by...

TOPICS:

Drug-Related Poisoning The Cause For Nearly 700,000 Emergency Department Visits a Year, According to New Research

March 16, 2011 9:32 am | by Bio-Medicine.Org | Comments

WASHINGTON, March 16, 2011 /PRNewswire-USNewswire/ -- New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians (ACEP) and the American Association of Poison Control Centers are raising awareness about the dangers...

TOPICS:

New PCMA Ad Campaign on SB 2445: Letting 'Fox Guard the Henhouse' Will Increase Health Care Costs

March 16, 2011 9:32 am | by Bio-Medicine.Org | Comments

WASHINGTON, March 16, 2011 /PRNewswire-USNewswire/ -- A new ad campaign warns Mississippi legislators that SB 2445 would increase health care costs by granting the State Board of Pharmacy (instead of the State Insurance Commissioner) authority to regulate pharmacy benefit managers...

TOPICS:
Advertisement

Dynatronics Selected for Inclusion in RB Milestone Portfolio

March 16, 2011 9:32 am | by Bio-Medicine.Org | Comments

SALT LAKE CITY, March 16, 2011 /- Dynatronics Corporation (Nasdaq: DYNT ) announced that it has been selected for inclusion in the RB Milestone Portfolio, a group of companies selected by RB Milestone Group, LLC ("RBMG"), to be introduced to the market via a combination of traditional and...

TOPICS:

Misonix Announces Change in Distribution of BoneScalpelâ„¢ Bone Cutting System in the U.S.

March 16, 2011 9:32 am | by Bio-Medicine.Org | Comments

FARMINGDALE, N.Y., March 16, 2011 /- Misonix, Inc. (Nasdaq: MSON ), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and...

TOPICS:

International Biotech Firm Funds Research Into Aging Through Foundation of UMDNJ

March 16, 2011 9:32 am | by Bio-Medicine.Org | Comments

NEW BRUNSWICK, N.J., March 16, 2011 /PRNewswire-USNewswire/ -- Working with the Foundation of UMDNJ and New Jersey Health Foundation, Rostock Biotech Research Ltd, headquartered in Moscow, Russia, has donated $100,000 to fund the research of Dr. Alexey G. Ryazanov, a professor in the...

TOPICS:

McGraw-Hill Professional and Simbionixâ„¢ Partner to Provide Enhanced Surgical Simulation and Education

March 16, 2011 7:35 am | by Bio-Medicine.Org | Comments

NEW YORK and CLEVELAND, March 16, 2011 /- McGraw-Hill Professional, a leading global provider of information resources for the scientific and medical communities, and Simbionix™, the world's leading provider of medical education and simulation technology, have partnered to bring...

TOPICS:

U.S. Breast Imaging Market to Nearly Double by 2017

March 16, 2011 7:32 am | by Diagnostic Imaging | Comments

The U.S. breast imaging and mammography markets are expected to not only recover from the recession, but nearly double in the next several years.

TOPICS:

Lantheus plans $150M private offering

March 16, 2011 6:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Lantheus Medical Imaging Inc. today said that it plans to offer $150 million in senior unsecured notes to enable it to make a distribution to its ultimate parent company, Lantheus MI Holdings Inc.

Bluebird bio forms potential $4.2M deal with French Muscular Dystrophy Association

March 16, 2011 6:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Bluebird bio, a Cambridge genetics-focused biotech firm, has entered into a deal, worth up to $4.2 million, with the French Muscular Dystrophy Association (AFM), and focused on the development of LentiGlobin, a treatment intended for beta-thalassemia and sickle cell anemia.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading